Design of immuno-enzymosomes with maximum enzyme targeting capability: effect of the enzyme density on the enzyme targeting capability and cell binding properties

被引:12
作者
Fonseca, MJ
Haisma, HJ
Klaasen, S
Vingerhoeds, MH
Storm, G
机构
[1] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, NL-3508 TB Utrecht, Netherlands
[2] Vrije Univ Amsterdam, Univ Hosp, Dept Med Oncol, Amsterdam, Netherlands
来源
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES | 1999年 / 1419卷 / 02期
关键词
liposome; antibody-directed enzyme prodrug therapy; ADEPT; enzyme targeting; cell binding;
D O I
10.1016/S0005-2736(99)00073-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immuno-enzymosomes have been proposed for the targeting of enzymes to cancer cells to achieve site specific activation of anticancer prodrugs. Previously, we reported that the enzyme beta-glucuronidase (GUS), capable of activating anthracycline-glucuronide prodrugs, can be coupled to the surface of inmunoliposomes directed against human ovarian cancer cells (OVCAR-3). This study aimed at the design of an immuno-enzymosome formulation with maximum enzyme targeting capability. By purification of the commercially available enzyme beta-glucuronidase (GUS), a 2-fold increase in the enzyme specific activity and a 4-fold increase in the enzymatic activity of immuno-enzymosomes was achieved. As a result, upon incubation with human ovarian cancer cells (OVCAR3), cell-associated enzymatic activity increased correspondingly. The optimized immuno-enzymosomes were shown to bind to the target cells in a specific fashion. Above a GUS/Fab' molar ratio of 0.5, impairment of the target cell binding ability of the immuno-enzymosomes was observed. This was likely due to a steric hindrance effect mediated by the presence of large amounts of bulky GUS molecules on the liposome surface. Nevertheless, increasing the GUS density on the surface of the immuno-enzymosomes to levels by far exceeding the GUS/Fab' molar ratio of 0.5, yielded a considerably Improved enzyme targeting capability. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:272 / 282
页数:11
相关论文
共 24 条
[1]   A CYTO-TOXIC AGENT CAN BE GENERATED SELECTIVELY AT CANCER SITES [J].
BAGSHAWE, KD ;
SPRINGER, CJ ;
SEARLE, F ;
ANTONIW, P ;
SHARMA, SK ;
MELTON, RG ;
SHERWOOD, RF .
BRITISH JOURNAL OF CANCER, 1988, 58 (06) :700-703
[2]   TARGETING OF ANTI-THY-1.1 MONOCLONAL-ANTIBODY CONJUGATED LIPOSOMES IN THY-1.1 MICE AFTER INTRAVENOUS ADMINISTRATION [J].
DEBS, RJ ;
HEATH, TD ;
PAPAHADJOPOULOS, D .
BIOCHIMICA ET BIOPHYSICA ACTA, 1987, 901 (02) :183-190
[3]   TARGETING ENZYMES FOR CANCER-THERAPY - OLD ENZYMES IN NEW ROLES [J].
DEONARAIN, MP ;
EPENETOS, AA .
BRITISH JOURNAL OF CANCER, 1994, 70 (05) :786-794
[4]   A NEW REAGENT WHICH MAY BE USED TO INTRODUCE SULFHYDRYL-GROUPS INTO PROTEINS, AND ITS USE IN THE PREPARATION OF CONJUGATES FOR IMMUNOASSAY [J].
DUNCAN, RJS ;
WESTON, PD ;
WRIGGLESWORTH, R .
ANALYTICAL BIOCHEMISTRY, 1983, 132 (01) :68-73
[5]  
EDWARDS DP, 1986, CANCER RES, V46, P1306
[6]   ANALYSIS OF A CONJUGATE BETWEEN ANTICARCINOEMBRYONIC ANTIGEN MONOCLONAL-ANTIBODY AND ALKALINE-PHOSPHATASE FOR SPECIFIC ACTIVATION OF THE PRODRUG ETOPOSIDE PHOSPHATE [J].
HAISMA, HJ ;
BOVEN, E ;
VANMUIJEN, M ;
DEVRIES, R ;
PINEDO, HM .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1992, 34 (05) :343-348
[7]   A MONOCLONAL ANTIBODY-BETA-GLUCURONIDASE CONJUGATE AS ACTIVATOR OF THE PRODRUG EPIRUBICIN-GLUCURONIDE FOR SPECIFIC TREATMENT OF CANCER [J].
HAISMA, HJ ;
BOVEN, E ;
VANMUIJEN, M ;
DEJONG, J ;
VANDERVIJGH, WJF ;
PINEDO, HM .
BRITISH JOURNAL OF CANCER, 1992, 66 (03) :474-478
[8]  
HAMILTON TC, 1983, CANCER RES, V43, P5379
[9]   Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy [J].
Houba, PHJ ;
Leenders, RGG ;
Boven, E ;
Scheeren, JW ;
Pinedo, HM ;
Haisma, HJ .
BIOCHEMICAL PHARMACOLOGY, 1996, 52 (03) :455-463
[10]   CHARACTERIZATION OF LIPOSOMES - THE INFLUENCE OF EXTRUSION OF MULTILAMELLAR VESICLES THROUGH POLYCARBONATE MEMBRANES ON PARTICLE-SIZE, PARTICLE-SIZE DISTRIBUTION AND NUMBER OF BILAYERS [J].
JOUSMA, H ;
TALSMA, H ;
SPIES, F ;
JOOSTEN, JGH ;
JUNGINGER, HE ;
CROMMELIN, DJA .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1987, 35 (03) :263-274